March 17, 2026. 14 cannabis news items, curated from live RSS feeds. Sorted by relevance score.
Texas hemp businesses brace for stricter THC rules starting March 31 | myfoxzone.com
# Summary Texas will enforce stricter THC limits (0.3% maximum) for hemp products starting March 31, affecting state cannabis businesses and product availability.
Read more →Texas hemp business owners fear impact of stricter THC regulations taking effect March 31
# Summary Texas hemp businesses face potential operational impacts from March 31 regulations lowering THC limits to include THCA, a cannabinoid precursor with emerging therapeutic research interest.
Read more →States move to tighten hemp THC rules ahead of federal ban – MJBizDaily
# Summary States are implementing stricter THC limits for hemp products as federal regulations tighten, with clinical implications for cannabinoid standardization and patient safety monitoring.
Read more →The $300 a week medicine Daniel feels better without – SMH
# Summary A University of Sydney study examines medicinal cannabis efficacy, referencing Therapeutic Goods Administration regulatory submissions regarding patient outcomes and treatment effectiveness.
Read more →Colombian Researcher Creates Cannabis-based Therapies for Sick Cats and Dogs
A Colombian researcher is developing cannabis-based therapeutic treatments for cats and dogs, targeting the endocannabinoid system to potentially manage pain, appetite, and mood-related conditions in animals.
Read more →Breakout Alert: ARTL – Small Cap Exclusive
Artelo Biosciences, a clinical-stage biopharmaceutical company, develops therapeutic drugs targeting the endocannabinoid system for potential medical applications.
Read more →Targeting the LPI/GPR55 Axis in MAFLD and MASH: Novel Insights, Therapeutic Strategies …
# Summary This article examines GPR55 receptor signaling pathways as a potential therapeutic target for metabolic-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatohepatitis (MASH).
Read more →State officials urge safe cannabis storage during National Poison Prevention Week
# Article Summary State cannabis officials promote safe storage practices during National Poison Prevention Week to reduce accidental poisoning risks, particularly among children.
Read more →Do you use cannabis for mental health symptoms? – YouTube
# Summary A study questions cannabis efficacy for mental health symptoms, suggesting users may not achieve therapeutic benefits from this treatment approach.
Read more →New study suggests marijuana won’t ease anxiety, common mental health problems
Recent research indicates marijuana is ineffective for treating anxiety and other mental health conditions including anorexia nervosa and bipolar disorder.
Read more →New study suggests marijuana won’t ease anxiety, common mental health problems – KKTV
New research indicates marijuana is ineffective for treating anxiety and depression, challenging common assumptions about its therapeutic potential for these prevalent mental health conditions.
Read more →Medical cannabis not effective as a mental health treatment, finds meta analysis
A meta-analysis examined medical cannabis effectiveness for mental health treatment and found it ineffective, though industry stakeholders questioned the study’s conclusions.
Read more →Scientists say marijuana doesn’t ease anxiety or other mental health conditions – 6abc Philadelphia
# Article Summary Research indicates marijuana does not alleviate anxiety or mental health symptoms and may increase psychosis risk in genetically predisposed individuals.
Read more →Will Spanberger allow marijuana marketplace to begin as planned or push the start date back?
# Summary Governor Abigail Spanberger is evaluating legislation regarding the timeline for beginning retail marijuana sales in Virginia, with a proposed January 1st start date.
Read more →Clinical Commentary
# Clinical Reflection These items collectively signal a critical inflection point where cannabis medicine practice faces simultaneous regulatory tightening (THC caps, THCA reclassification) and evidence-based pushback against unsubstantiated mental health claims, requiring practitioners to recalibrate patient selection toward conditions with stronger mechanistic support (veterinary pain, metabolic dysfunction via GPR55 modulation) while deprioritizing anxiety and mood disorders where recent meta-analyses show insufficient efficacy. The gap between patient demand for mental health applications and emerging negative trial data suggests we must have more candid conversations about cannabis’s actual therapeutic window rather than relying on patient testimonials or theoretical endocannabinoid reasoning. Simultaneously, the regulatory environment’s narrowing definitions of “legal” cannabinoids underscores that clinical practice cannot remain tethered to
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: